Alaethes Wealth’s Biogen BIIB Stock Holding History

Alaethes Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11	Closed	-$2K	–	128
2022 Q1	$2K	Sell	11 -15	-58%	-$3.26K	﹤0.01%	270
2021 Q4	$6K	Hold	26	–	–	﹤0.01%	225
2021 Q3	$7K	Hold	26	–	–	0.01%	205
2021 Q2	$9K	Buy	+26	New	+$7.88K	0.01%	192

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Alaethes Wealth's BIIB Position: Q2 2022 in Review

Alaethes Wealth sold out of Biogen (BIIB) in Q2 2022, closing a stake of 11 shares — an estimated $2K sold.

Alaethes Wealth first reported a position in BIIB in Q2 2021 and held it in 4 quarters. The position peaked at $9K in Q2 2021. 927 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

Alaethes Wealth reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
Alaethes Wealth sold 11 Biogen shares in Q2 2022, an estimated $2K.
Alaethes Wealth first reported a position in Biogen in Q2 2021 and held it in 4 quarters.
Alaethes Wealth's Biogen position peaked at $9K in Q2 2021.
927 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Alaethes Wealth's 13F filing for Q2 2022, filed 16 Aug 2022.